Abstract
Neoplastic meningitis is a feared complication in cancer patients, the median survival ranging from some weeks to a few months. Management is palliative and aims to provide symptoms relief while delaying neurological deterioration.
Intrathecal methotrexate and/or cytarabine is the most widely used treatment in such clinical situations. These drugs are administered 2 or 5 times a week— a circumstance that is both bothersome for the patient and time-costly for the medical personnel. Liposomal cytarabine is a sustained-release cytarabine formulation specifically developed for the treatment of neoplastic meningitis. Its administration on a twice-weekly basis ensures sustained cytotoxic drug concentrations in cerebrospinal fluid. Controlled clinical trials have shown liposomal cytarabine to be equally or more effective than the classical treatment for neoplastic meningitis. In lymphomatous meningitis, liposomal cytarabine offers superior response rates, improved patient quality of life, and a prolongation of the time to neurological progression. When the cause of meningitis is a solid tumor, liposomal cytarabine prolongs the time to neurological progression and improves quality of life.
These observations indicate that DepoCyte®, is a convenient treatment for patients with neoplastic meningitis, due to its efficacy and easy of administration characteristics.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Herman TS, Hammond N, Jones SE, et al. Involvement of the central nervous system by non-Hodgkin's lymphoma: the Southwest Oncology Group experience. Cancer. 1979;43:390–7.
Bleyer WA. Leptomeningeal cancer in leukaemia and solid tumors. Curr Probl Cancer. 1988;12:184–238.
Wasserstrom, W,, Glass JP, Posner JB, et al. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49:759–72.
Boogerd W, Hart AAM, Van der Sande JJ, et al. Meningeal cardinomatosis in breast cancer. Cancer. 1991;67:1685–95.
Chamberlain MC, Kormanik PA. Non-AIDS-related lymphomatous meningitis: combined modality therapy. Neurology. 1997;49:1728–31.
Chamberlain MC, Dirr L. Involved filed radiotherapy and intra-ommaya methotrexate/ara-C in patients with AIDS-related lymphomatous meningitis. J Clin Oncol. 1993;11:1979–84.
Giannone L, Greco FA, Hainsworth JD, et al. Combination intaventricular chemotherapy for meningeal neoplasia. J Clin Oncol. 1986;4:68–73.
Grossman SA, Finkelstein MD, Ruckdeschek JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol. 1993;11: 561–9.
Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol. 1987;5:1655–62.
Graham FL, Whitmore GF. The effect of 1-beta-D-arabinofuranosylcytosine on growth, viability, and DNA syntesis of mouse L-cells. Cancer Res. 1970;30:2627–35.
Zimm S, Collins JM, Miser J, et al. Cytosine arabinoside cerebrospinalfluid kinetics. Clin Pharmacol Ther. 1984; 35:826–30.
Kohn FR, Malkmus SA, Brownson EA, et al. Fate of the predominant phospholipid component of DepoFoam drug delivery matrix after intrathecal administration of sustained-release encapsulated cytarabine in rats. Drugs Delivery. 1998;5:143–51.
Chamberlain MC, Kormanik P, Howell SB, Kim S. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol. 1995;52:912–7.
Frei E, Bickers JN, Hewlett JS, et al. Dose schedule and antitumor studies of arabinosyl cytosine (NSSC 63878). Cancer Res. 1969;29:1325–32.
Kim S, Chatelut E, Kim JC, et al. Extended CSF citarabine exposure following intrathecal administration of DTC 101. J Clin Oncol. 1993;11:2186–93.
Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E, Kim S. Treatment of leptomenigeal metastasis with intraventicular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol. 1993;50:261–4.
Glantz MJ, Lafollete S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110–6.
Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5:3394–402.
Jaeckle KA, Phuphanich S, Bent MJ, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer. 2001;84:157–63.
Jaeckle KA, Batchelor T, O'Day SJ, et al. An open label trial of sustsined-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol. 2002;57:231–9.
Haioum C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated an receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d’Etudes des Lymphomes de l’Adulte. Ann Oncol. 2000; 11:685–90.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Domínguez, A.R., Hidalgo, D.O., Garrido, R.V. et al. Liposomal cytarabine (DepoCyte®) for the treatment of neoplastic meningitis. Clin Transl Oncol 7, 232–238 (2005). https://doi.org/10.1007/BF02710168
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02710168